Share on StockTwits

Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Richard K. Prins bought 4,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 18th. The stock was purchased at an average price of $10.02 per share, for a total transaction of $40,080.00. Following the completion of the purchase, the director now directly owns 36,051 shares of the company’s stock, valued at approximately $361,231. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on AMPH. Analysts at Jefferies Group raised their price target on shares of Amphastar Pharmaceuticals from $14.00 to $15.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Amphastar Pharmaceuticals from $17.00 to $18.00 in a research note on Wednesday, August 6th. Finally, analysts at Needham & Company LLC initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $17.00 price target on the stock.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down 0.10% on Tuesday, hitting $10.01. The stock had a trading volume of 101,211 shares. Amphastar Pharmaceuticals has a one year low of $6.67 and a one year high of $11.07. The stock’s 50-day moving average is $9.40 and its 200-day moving average is $9.44. The company’s market cap is $434.5 million.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Tuesday, August 12th. The company reported $0.02 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.11) by $0.13. On average, analysts predict that Amphastar Pharmaceuticals will post $-0.22 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.